AMP is the consulting practice of Drs. Mitali Stevens, PharmD, BCPS, and Phillip J. Stevens, PhD, MBA, who help start-ups and established medtech, biotech and pharmaceutical companies with limited market access and business development capacity. We help you develop and execute systematic strategies that integrate health economics, outcomes research and market access solutions across all stages of the product life cycle, and to expand company portfolios and the international reach, to ensure a competitive advantage and commercial success.
Market Access, Reimbursement and Evidence Strategy
Alliance Management
Business Development
Dr. Mitali Stevens brings more than two decades of experience developing evidence strategies and implementing market access tactics that demonstrate clinical and economic product value. She drove the development of RWE generation and reimbursement strategies to enhance market access through publications, economic models, value dossiers, case studies, and other educational materials. She served as a field-based liaison supporting Managed Markets, Medical Affairs, and HEOR teams for various pharmaceutical companies and she understands the importance of gathering critical voice of customer data from relevant stakeholders earlier on in the development of the commercialization strategy. She has executed the HEOR value proposition through formulary presentations of scientific data and economic models to key stakeholders at national and regional MCOs, IDNs, ACOs, LTC, GPOs, PBMs and Home Health Care with successful outcomes, such as formulary inclusion and implementation of quality initiatives to support product value proposition. She received her Doctor of Pharmacy from The Ohio State University, is a registered pharmacist and holds a board certification in pharmacotherapy specialty (BCPS).
Dr. Phillip Stevens brings two decades of experience in pharmaceuticals and biotech, having been responsible for drug development, project and program management, alliance management and business development. Most recently, he was Executive Director Business Development and Global Alliances at Elevar Therapeutics Inc, where he helped in-license Camrelizumab, and PD-1 inhibitor, from Jiangsu Hengrui, a deal with potential value of $1B+. He has managed dozens of alliances and internal programs, bringing products to approval in the US (Viread® Oral Powder, Lamictal ODT®, Propranolol ER Capsules, Evomela®, Khapzory®) and EX-US, including Canada (Folotyn®, Zevalin®), China (Evomela), Colombia (Beleodaq®) and Japan (Folotyn). He received his PhD in Pharmaceutical Sciences from The Ohio State University, MBA from the University of Dayton, and holds a PMP certificate.
Strategize to AMPlify your product reach
Need insights on navigating the complex market access environment and understanding your hurdles and opportunities?
It is never too early to start thinking about your market access strategy, reimbursement hurdles and planning for evidence that moves the needle
Tactical implementation in reimbursement and HEOR can have many moving parts. Need an extra set of hands to guide your teams?
Contact AMP Stevens and Associates LLC for your Market Access, Reimbursement and Evidence needs today!